Perrigo Company plc (NYSE:PRGO) Receives $19.33 Consensus Target Price from Brokerages

Perrigo Company plc (NYSE:PRGO) has been assigned a consensus recommendation of “Reduce” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $19.3333.

Several equities research analysts have recently commented on the stock. Zacks Research lowered shares of Perrigo from a “hold” rating to a “strong sell” rating in a research report on Friday, March 20th. Jefferies Financial Group restated a “hold” rating on shares of Perrigo in a research report on Thursday, February 26th. Canaccord Genuity Group reduced their target price on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a report on Friday, February 27th. JPMorgan Chase & Co. decreased their price target on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Perrigo in a research note on Monday, December 22nd.

Perrigo Stock Performance

PRGO stock opened at $9.53 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.76 and a quick ratio of 1.63. Perrigo has a 1 year low of $9.23 and a 1 year high of $28.43. The company has a market cap of $1.31 billion, a P/E ratio of -0.93, a price-to-earnings-growth ratio of 1.13 and a beta of 0.41. The stock’s fifty day moving average price is $12.74 and its 200-day moving average price is $15.55.

Perrigo (NYSE:PRGO) last posted its earnings results on Thursday, February 26th. The company reported $0.77 earnings per share for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. Perrigo had a negative net margin of 33.51% and a positive return on equity of 9.41%. The firm’s revenue was down 2.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.93 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, equities analysts forecast that Perrigo will post 2.56 earnings per share for the current year.

Perrigo Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 24th. Investors of record on Monday, March 2nd were given a dividend of $0.29 per share. The ex-dividend date was Monday, March 2nd. This represents a $1.16 annualized dividend and a yield of 12.2%. Perrigo’s payout ratio is -11.28%.

Institutional Trading of Perrigo

A number of hedge funds and other institutional investors have recently bought and sold shares of PRGO. EverSource Wealth Advisors LLC lifted its position in shares of Perrigo by 116.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after buying an additional 1,014 shares in the last quarter. Geneos Wealth Management Inc. increased its holdings in Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after acquiring an additional 786 shares in the last quarter. UMB Bank n.a. raised its stake in Perrigo by 161.5% during the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after acquiring an additional 1,213 shares during the period. Meeder Asset Management Inc. bought a new stake in Perrigo during the 4th quarter worth approximately $28,000. Finally, CWM LLC lifted its holdings in Perrigo by 230.0% during the fourth quarter. CWM LLC now owns 2,191 shares of the company’s stock valued at $31,000 after purchasing an additional 1,527 shares in the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.